Antiretroviral therapy and adverse pregnancy outcome: The elephant in the room?

Journal of Infectious Diseases

Volumn 213, Issue 7, 2016, Pages 1051-1054

  Mofenson, Lynne M ^a  

^a ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION   (United States)

Author keywords

Antiretroviral therapy; HIV infection; Pregnancy; Prematurity

Indexed keywords

ANTICONVULSIVE AGENT; ANTIRETROVIRUS AGENT; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VALPROIC ACID; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADVERSE OUTCOME; CD4 LYMPHOCYTE COUNT; CONGENITAL MALFORMATION; DISEASE SEVERITY; DRUG SAFETY; EPIDEMIC; EPILEPSY; HIGH RISK PREGNANCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATERNAL HYPERTENSION; NEWBORN DEATH; NOTE; PREECLAMPSIA; PREGNANCY OUTCOME; PREGNANT WOMAN; PREMATURITY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; SEIZURE; SMALL FOR DATE INFANT; STILLBIRTH; VERTICAL TRANSMISSION; VIRUS TRANSMISSION; ADVERSE EFFECTS; CHEMICALLY INDUCED; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; LOW BIRTH WEIGHT; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; INFANT, LOW BIRTH WEIGHT; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREMATURE BIRTH;

EID: 84962555880     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv390     Document Type: Note

References (40)

1. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva, Switzerland, 2013. http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727-eng.pdf. Accessed 13 July 2015.
2. The Interagency Task Team on the Prevention and Treatment of HIV Infection in Pregnant Women, Mothers and Children (IATT). Option B+ countries and PMTCT regimen, 2015. http://www.emtct-iatt.org/b-countries-and-pmtct-regimen/. Accessed 13 July 2015.
3. European Collaborative Study. Mother to child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40:458-65.
4. Townsend CL, Byrne L, Cortina-Borja M, et al. Earlier initiation of ART and further decline in motherto- child HIV transmission rates, 2000-2011. AIDS 2014; 28:1049-57.
5. Hoffman RM, Black V, Technau K, et al. Effects of highly active antiretroviral therapy duration and regimen on risk for mother-to-child transmission of HIV in Johannesburg, South Africa. JAIDS 2010; 54:35-41.
6. Mandelbrot L, Tubiana R, Le Chenadec J, et al. No perinatal transmission of HIV-1 in women efficiently treated since conception. In: Abs # 867. 22st Conference on Retroviruses and Opportunistic Infections (CROI), 23-26 February 2015, Seatle, Washington, 2015.
7. National Institute of Allergy and Infectious Diseases. NIH News: Starting antiretroviral treatment early improves outcomes for HIV-infected individuals: NIH-funded trial results likely will impact global treatment guidelines. http://www.niaid.nih.gov/news/newsreleases/2015/Pages/START.aspx. Accessed 13 July 2015.
8. Joint United Nations Programme on HIV/AIDS (UNAIDS). Implications for the START study data - questions and answers. Geneva, Switzerland, 2015. http://www.unaids.org/en/resources/docu ments/2015/2015-Implications-of-the-START- study-data. Accessed 13 July 2015.
9. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998; 338:1128-37.
10. Borthen I. Obstetrical complications in women with epilepsy. Seizure 2015; 28:26-8.
11. Tomson T, Xue H, Battino D. Major congenital malformations in children of women with epilepsy. Seizure 2015; 28:40-4.
12. Bromley R, Weston J, Adab N, et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst Rev 2014; 10:CD010236.
13. Kamyar M, Varner M. Epilepsy in pregnancy. Clin Obstet Gynecol 2013; 56:330-41.
14. Adab N, Tudur SC, Vinten J, Williamson P, Winterbottom J. Common antiepileptic drugs in pregnancy in women with epilepsy. Cochrane Database Syst Rev 2004; CD004848.
15. Newell ML, Bunders MJ. Safety of antiretroviral drugs in pregnancy and breastfeeding for mother and child. Curr Opin HIV AIDS 2013; 8:504-10.
16. Mofenson LM. Editorial commentary: new challenges in the elimination of pediatric HIV infection: the expanding population of HIV-exposed but uninfected children. Clin Infect Dis 2015; 60: 1357-60.
17. Li N, Sando MM, Spiegelman D, et al. Antiretroviral therapy in relation to birth outcomes among HIVinfected women: a cohort study. J Infect Dis 2016; 213:1057-64.
18. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Accessed 13 July 2015.
19. Ford N, Mofenson L, Shubber Z, et al. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS 2014; 28(suppl 2):S123-31.
20. Kourtis AP, Fowler MG. Antiretroviral drug use during pregnancy and risk of preterm delivery: more questions than answers. J Infect Dis 2011; 204:493-4.
21. Powis KM, Kitch D, Ogwu A, et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis 2011; 204:506-14.
22. Fowler M, Qin M, Shapiro D, Fiscus S. PROMISE: Efficacy and safety of two strategies to prevent perinatal HIV transmission. In: Abs # 31 LB. 22st Conference on Retroviruses and Opportunistic Infections (CROI), 23-26 February 2015; Seattle, Washington, 2015.
23. Koss CA, Natureeba P, Plenty A, et al. Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir-ritonaviror efavirenz-based antiretroviral therapy. JAIDS 2014; 67:128-35.
24. Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis 2012; 206:1695-705.
25. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of preterm delivery: a metaanalysis. AIDS 2007; 21:607-15.
26. Sibiude J, Warszawski J, Tubiana R, et al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost? Clin Infect Dis 2012; 54:1348-60.
27. Piccinni MP, Lombardelli L, Logiodice F, et al. T helper cell mediated-tolerance towards fetal allograft in successful pregnancy. Clin Mol Allergy 2015; 13:9.
28. Klein SA, Dobmeyer JM, Dobmeyer TS, et al. Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cytoplasmic cytokine detection on single cell level by flow cytometry. AIDS 1997; 11:1111-8.
29. Osakwe CE, Bleotu C, Chifiriuc MC, et al. TH1/TH2 cytokine levels as an indicator for disease progression in human immunodeficiency virus type 1 infection and response to antiretroviral therapy. Roum Arch Microbiol Immunol 2010; 69: 24-34.
30. Powis KM, Shapiro RL. Protease inhibitors and adverse birth outcomes: is progesterone the missing piece to the puzzle? J Infect Dis 2015; 211:4-7.
31. Fiore S, Newell ML, Trabattoni D, et al. Antiretroviral therapy-associated modulation of Th1 and Th2 immune responses in HIV-infected pregnant women. J Reprod Immunol 2006; 70:143-50.
32. Faye A, Pornprasert S, Mary JY, et al. Characterization of the main placental cytokine profiles from HIV-1-infected pregnant women treated with antiretroviral drugs in France. Clin Exp Immunol 2007; 149:430-9.
33. Haffejee F, Naicker T, Singh M, Moodley J. Placental leptin in HIV-associated preeclampsia. Eur J Obstet Gynecol Reprod Biol 2013; 171:271-6.
34. Papp E, Mohammadi H, Loutfy MR, et al. HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction. J Infect Dis 2015; 211:10-8.
35. Shapiro RL, Souda S, Parekh N, et al. High prevalence of hypertension and placental insufficiency, but no in utero HIV transmission, among women on HAART with stillbirths in Botswana. PLOS One 2012; 7:e31580.
36. Wimalasundera RC, Larbalestier N, Smith JH, et al. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet 2002; 360:1152-4.
37. Suy A, Martinez E, Coll O, et al. Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. AIDS 2006; 20:59-66.
38. Katz J, Lee AC, Kozuki N, et al., for CHERG Smallfor- Gestational-Age-Preterm BirthWorking Group. Mortality risk in preterm and small-for-gestationalage infants in low-income and middle-income countries: a pooled country analysis. Lancet 2013; 382:417-25.
39. Ades V, Mwesigwa J, Natureeba P, et al. Neonatal mortality in HIV-exposed infants born to women receiving combination antiretroviral therapy in Rural Uganda. J Trop Pediatr 2013; 59:441-6.
40. United Nations Children's Fund (UNICEF). Towards an AIDS-free generation: children and AIDS, sixth stocktaking report, 2013. New York: UNICEF.